72700-23-3

Basic information

• Product Name: 4-Chloro-6,7-methylenedioxyquinazoline
• Synonyms: 4-Chloro-6,7-methylenedioxyquinazoline
• CAS NO: 72700-23-3
• Molecular Formula: C₉H₅ClN₂O₂
• Molecular Weight: 208.6012
• Product Categories: Heterocycles series
• Mol File: 72700-23-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 360.3 °C at 760 mmHg
• Flash Point: 171.7 °C
• Appearance: /
• Density: 1.566 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Chloro-6,7-methylenedioxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6,7-methylenedioxyquinazoline(72700-23-3)
• EPA Substance Registry System: 4-Chloro-6,7-methylenedioxyquinazoline(72700-23-3)

Safety Data

• Hazardous Substances Data: 72700-23-3(Hazardous Substances Data)

Usage

General Description

4-Chloro-6,7-methylenedioxyquinazoline is a chemical compound that belongs to the quinazoline class of compounds. It is a heterocyclic compound with a chlorine atom and a methylenedioxy group attached to the quinazoline ring. 4-Chloro-6,7-methylenedioxyquinazoline has potential applications in pharmaceutical research and drug development, as quinazolines have been studied for their diverse biological activities, including anticancer, antimalarial, and antimicrobial properties. The specific properties and potential applications of 4-Chloro-6,7-methylenedioxyquinazoline in the field of drug discovery and medicinal chemistry would require further investigation and research.

Upstream product

• 593-71-5 Chloroiodomethane 
• 1145671-36-8 4-chloro-6,7-dihydroxyquinazoline 
• 269-53-4 [1,3]dioxolo[4,5-g]quinazoline 
• 165330-00-7 ethyl (1,3-benzodioxolan-5-yl)carbamate 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 721-00-6 methyl 6-nitrobenzo[d][1,3]dioxole-5-carboxylate 
• 326-56-7 methyl 3,4-methylenedioxybenzoate 
• 40680-63-5 methyl 6-aminobenzo[d][1,3]dioxole-5-carboxylate 
• 94-53-1 Piperonylic acid 
• 28310-11-4 6,7-methylenedioxyquinazoline-4(3H)-one 

Downstream Products

• 1256394-35-0 4-(N-methyl-3-chloro-4-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 1256394-36-1 4-(N-methyl-4-bromo-2-fluoroanilino)-6,7-methylenedioxyquinazoline 
• 1456819-60-5 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-methansulfonamidopheyl)amine hydrochloride 
• 1401243-68-2 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(biphenyl-3'-yl)amine hydrochloride 
• 1355620-31-3 5-(5-{2H-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy}pyridin-2-yl)-2-[(4-fluorophenyl)amino]-3-methyl-3-pyrimidin-4-one 
• 1348516-27-7 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-bromophenyl)amine hydrochloride 
• 1348211-74-4 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-methylphenyl)amine hydrochloride 
• 1348218-00-7 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-trifluoromethylphenyl)amine hydrochloride 
• 1266869-09-3 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(4'-bromo-2'-fluorophenyl)amine hydrochloride 
• 1266868-75-0 ([1,3]dioxolo[4,5-g]quinazolin-8-yl)-(3'-chloro-4'-fluorophenyl)amine hydrochloride 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING CANCER

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties

In this work the synthesis and the biological evaluation of some novel anilinoquinazoline derivatives carrying modifications in the quinazoline scaffold and in the aniline moiety were reported. Preliminary cytotoxicity studies identified three derivatives

Exploring Epidermal Growth Factor Receptor (EGFR) inhibitor features: The role of fused dioxygenated rings on the quinazoline scaffold

A number of dioxolane, dioxane, and dioxepine quinazoline derivatives have been synthetized, and evaluated as EGFR inhibitors. Their cytotoxic activity has been tested against two cell, lines overexpressing and not expressing EGFR. Most derivatives were a